PY314 

PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8⁺ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors^[1][2][3][4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

PY314 can be used in research of advanced solid tumors, when combined wtih Pembrolizumab (HY-P9902)^[2].
PY314 is well tolerated and has an excellent safety profile both as a single agent and in combination with Pembrolizumab[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

54209  [NCBI]

Q9NZC2-1

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.24 kDa

Liquid

Colorless to light yellow

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow cytometric analysis of 1.5×10⁶ THP-1 cells with PY314 (HY-P990651, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Oladapo Yeku, et al. Evaluation of myeloid targeting agents, PY159 and PY314, in two dose expansion phase Ib trials in platinum-resistant ovarian cancer. December 2023Immuno-Oncology Technology 20:100598.

  [2]. Yeku OO, et al. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025;13(3):e010959. Published 2025 Mar 13.

  [3]. Wang Y, et al. The emerging role of triggering receptor expressed on myeloid cell-2 in malignant tumor. Cent Eur J Immunol. 2022;47(4):373-381.

  [4]. Amita Patnaik, et al. A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody. June 2022. Journal of Clinical Oncology 40(16_suppl):2648-2648.